Journal of Asthma最新文献

{"title":"Antibody response to SARS-CoV-2 vaccine in patients with asthma.","authors":"Xiaoqin Zhang, Yifei Tao, Zhu Song, Lina Sun, Yongchang Sun, Rong Jin, Chun Chang","doi":"10.1080/02770903.2025.2458523","DOIUrl":"10.1080/02770903.2025.2458523","url":null,"abstract":"<p><strong>Background: </strong>Viral infections constitute a primary trigger for asthma exacerbations. While vaccines protect against viral infections by eliciting a Th1 immune response, the impact of the asthmatic immune milieu which is characterized by Th2 cytokine dominance and elevated IgE levels on post-vaccination antibody production remains elusive. Therefore, vaccination protocols tailored to asthma patients need to be formulated.</p><p><strong>Methods: </strong>The levels of IgG specific for SARS-CoV-2 S protein were measured in the sera of vaccinated and unvaccinated individuals by ELISA. The differences in antibody titers between asthma patients and healthy controls, as well as among distinct asthma subgroups were analyzed.</p><p><strong>Results: </strong>The vaccinated individuals had significantly elevated serum antibody levels compared to their unvaccinated counterparts. There were no significant differences in the antibody titers of asthma patients and healthy controls after completion of the three-dose vaccination regimen. Furthermore, no discernible variations in antibody titers were detected among the asthma subgroups.</p><p><strong>Conclusion: </strong>Asthma patients can safely adhere to the same vaccination strategies as the general healthy population, negating the need for any specialized vaccination protocols based solely on the asthmatic immune landscape.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effectiveness and safety of mepolizumab in elderly patients with severe asthma: insights from the REDES study.","authors":"Eva Martínez-Moragón, Celia Pinedo, Luis Puente-Maestu, Mariana Muñoz-Esquerre, Ana Gómez-Bastero, Jacinto Ramos, Miguel Díaz-Palacios, Tamara Hermida, David Bañas-Conejero, Santiago Quirce","doi":"10.1080/02770903.2025.2463956","DOIUrl":"10.1080/02770903.2025.2463956","url":null,"abstract":"<p><strong>Objective: </strong>Asthma and severe asthma are problems affecting all age groups, but asthma is frequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lack of fitness, and presence of multiple comorbidities. Even so, the proportion of patients with severe asthma aged ≥65 is significant, and data on efficacy of asthma medications in the elderly are sometimes limited. We report here the effectiveness and safety of mepolizumab (an IL-5 inhibitor) in elderly (≥65 years) patients.</p><p><strong>Methods: </strong>The REDES study was an observational, multicenter study of the effectiveness and safety of mepolizumab 100 mg SC every 4 weeks in 318 severe asthma patients in Spain. This post-hoc analysis compares the effectiveness and safety of patients ≥65 years old to patients <65 years after 12 months of mepolizumab treatment.</p><p><strong>Results: </strong>27% of patients were ≥65 years old, compared with 73% of patients <65 years. Elderly patients showed a trend toward less frequent comorbid nasal polyps (<i>p</i> = 0.06) and a lower proportion of atopic sensitization (as detected by prick test or specific IgE) (<i>p</i> = 0.02). Similar improvements were noted in ACT score (<i>p</i> < 0.0001), comparable exacerbation reductions (<i>p</i> < 0.0001), and lung function parameters (<i>p</i> < 0.04 in elder group and <i>p</i> < 0.0001 in younger elder group), although an apparent greater reduction of OCS daily dose was observed in elder patients (<i>p</i> = 0.0002). No new safety signals were reported in the elderly population.</p><p><strong>Conclusions: </strong>This study further supports mepolizumab as an effective and well tolerated therapy in the difficult to treat population of elderly patients with severe asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-5"},"PeriodicalIF":1.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing serum and biopsy biomarkers for predicting allergic asthma severity: a comprehensive study.","authors":"Zainab Khaleel Mohammed, Shukur Wasman Smail, Christer Janson, Kawa Amin","doi":"10.1080/02770903.2025.2463953","DOIUrl":"10.1080/02770903.2025.2463953","url":null,"abstract":"<p><strong>Background: </strong>Allergic asthma is a chronic respiratory condition characterized by inflammation and constriction of the airways in response to specific allergens. This study aimed to assess serum and biopsy biomarkers to predict the severity of allergic asthma.</p><p><strong>Methods: </strong>A total of 18 allergic asthma patients and 15 healthy controls (HCs) were included from April to August 2021 in Par hospital, Erbil-Iraq. The blood and bronchial biopsy were taken, the serum biopsy marker were assessed <i>via</i> ELISA and immunohistochemistry (IHC) methods.</p><p><strong>Results: </strong>It was showed no significant difference in age between allergic asthma patients and HCs (<i>p</i> = 0.285), although patients with allergic asthma had a significantly higher BMI (<i>p</i> = 0.028). Allergic asthma patients exhibited significantly elevated levels of serum eosinophil cationic protein (ECP), fibroblast growth factor 23 (FGF-23), and fibroblast growth factor 18 (FGF-18) compared to HCs (<i>p</i> < 0.0001). IHC analysis revealed significantly higher levels of myeloperoxidase (MPO) positive cells, activated eosinophils (EG2) positive cells, mast cells, FGF-18 positive cells, and FGF-23 positive cells in bronchial biopsy samples from allergic asthma patients compared to HCs (<i>p</i> < 0.0001). Additionally, serum FGF-18, EG2 positive cells, and FGF-18 positive cells were negatively correlated with lung function (FEV1/FVC), while asthma score showed a significant positive correlation with these markers.</p><p><strong>Conclusion: </strong>Serum FGF-18, EG2 positive cells, and FGF-18 positive cells are promising biomarkers that can predict improvements in the FEV1/FVC ratio and reductions in asthma score, highlighting their potential utility in assessing the severity of allergic asthma and guiding treatment decisions.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between asthma and risk of cardiovascular disease in Korean adults.","authors":"Jihye Jung, Jimin Sung, Sunwoo Kim, Jeonghu Kim, Chanbin Park, Minsu Sung, Sol Choi, Mi Ah Han","doi":"10.1080/02770903.2025.2463962","DOIUrl":"10.1080/02770903.2025.2463962","url":null,"abstract":"<p><strong>Objectives: </strong>Cardiovascular disease (CVD) is a major cause of death in Korea, and studies have reported that asthma can have a negative impact on CVD. This study aimed to identify the association between asthma and CVD, including the current status, treatment status, and duration of asthma in Korean adults.</p><p><strong>Methods: </strong>The Korea National Health and Nutrition Examination Survey (2016-2021) was used, and 34,384 adults aged 19 years or older were included. Exposures were asthma-related characteristics, and outcomes were hypertension, ischemic heart disease, and stroke. The association between asthma characteristics and CVD was analyzed using the chi-square test and multiple logistic regression analysis.</p><p><strong>Results: </strong>The asthma diagnosis experience rate of the population was 3.1%; 1.6% were currently suffering from asthma, 1.0% were receiving asthma treatment, 0.6% were receiving regular medication, and 1.5% had a disease duration of 11 years or more. The CVD diagnosis rates in the population were 20.2% for hypertension, 2.3% for ischemic heart disease, and 1.8% for stroke. Compared to those who had no asthma diagnosis, those who had been diagnosed with asthma (OR = 2.06, 95% CI = 1.47-2.87), received asthma treatment (OR = 1.93, 95% CI = 1.22-3.04), and had a long duration of asthma (OR = 3.54, 95% CI = 1.71-7.33) had a significantly higher risk of ischemic heart disease. However, hypertension and stroke were not significantly correlated with asthma-related characteristics.</p><p><strong>Conclusions: </strong>Asthma diagnosis and asthma-related characteristics were associated with an increased risk of ischemic heart disease. Our study suggests that research on risk assessment and management of CVD in patients with asthma would be needed.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-8"},"PeriodicalIF":1.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a cardboard-based spacer for enhancing aerosol delivery from pressurized metered dose inhalers.","authors":"Haitham Saeed, Wesam G Ammari, Hasnaa Osama, Ahmed M Abdelfattah, Mohamed E A Abdelrahim, Basma M E Mohamed","doi":"10.1080/02770903.2025.2463965","DOIUrl":"10.1080/02770903.2025.2463965","url":null,"abstract":"<p><strong>Objective: </strong>The current study aimed to evaluate a novel paper card-based spacer (MDI Plus) <i>in vitro</i> and <i>in vivo</i> as a cost-effective alternative to traditional spacers (AeroChamber Plus).</p><p><strong>Methodology: </strong>The <i>in vitro</i> part evaluated salbutamol's aerodynamic particle size distribution (APSD) after 0, 20, 50, 120, and 200 uses of Ventolin pressurized metered dose inhaler (pMDI) when connected to MDI Plus using an Andersen cascade impactor at an inhalation flow of 28.3 L/min. The <i>in vivo</i> part recruited a cohort of adult asthmatic patients. It assessed their pMDI usage and the number of training sessions to enhance their ability to use their pMDI alone and in combination with MDI Plus and AeroChamber Plus. Moreover, the amount of salbutamol deposited within the spacer devices, on the pMDI, and on the hand of the patients after 0, 20, 50, 120, and 200 uses were evaluated.</p><p><strong>Results: </strong>The durability tests revealed that while there were reductions in aerodynamic performance over the lifespan of the pMDI, the decreases were insufficient to render the spacer ineffective. The fine particle fraction decreased slightly, and the mass median aerodynamic diameter increased somewhat, but the spacer maintained functional performance. The study indicated that spacers significantly improved patients' ability to use their MDIs correctly with minimal training. The MDI Plus showed a slightly significant positive impact (<i>p</i> < 0.05), requiring fewer training sessions for effective use. The amount left in the MDI Plus was significantly lower than within the AeroChamber Plus (<i>p</i> < 0.05). The amount deposited on the MDI and the hands of the patients after multiple storage in the MDI Plus box and uses was insignificant and within the allowed limits.</p><p><strong>Conclusion: </strong>The MDI Plus simultaneously can act as an pMDI packaging box and spacer, serving as a practical, affordable, and accessible alternative to traditionally commercially available plastic spacers, particularly in resource-limited settings.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vocal cord dysfunction/inducible laryngeal obstruction induced by hyperventilation in healthy individuals, people with asthma, and following coronavirus infection.","authors":"Laurence E Ruane, Joo Koh, Malcolm Baxter, Paul Finlay, Kathy Low, Rachael Hillman, Lucy Ruane, Garun Hamilton, Paul Leong, Philip Bardin","doi":"10.1080/02770903.2025.2463979","DOIUrl":"10.1080/02770903.2025.2463979","url":null,"abstract":"<p><strong>Objective: </strong>Vocal cord dysfunction/inducible laryngeal obstruction (VCD/ILO) commonly co-exists with asthma and can start after viral infections. In this setting evidence suggests that dysfunctional breathing may induce the disorder but this possibility has not been researched. We therefore postulated that dysfunctional breathing can induce VCD/ILO, more so in people with asthma and after viral infections.</p><p><strong>Methods: </strong>Eight healthy control subjects, 16 people with asthma and eight people who had recent COVID-19 infection (three with asthma) were recruited. Video-recorded laryngoscopy was performed at tidal breathing and during controlled hyperventilation (used as a proxy for dysfunctional breathing). VCD/ILO was diagnosed by laryngoscopy using accepted criteria and correlated with study cohorts, clinical attributes, asthma severity and spirometry.</p><p><strong>Results: </strong>Overall, 32 subjects were studied. Hyperventilation was verified in all subjects. None of the healthy control group or people with mild asthma developed VCD/ILO during or after hyperventilation but one person with moderate/severe asthma had clear evidence of VCD/ILO. In contrast, in people who had COVID-19 infection, hyperventilation induced VCD/ILO in 3/8 people (38%).</p><p><strong>Conclusion: </strong>These proof-of-concept studies suggest that hyperventilation can provoke VCD/ILO in asthma and after a recent viral infection. How and why VCD/ILO develops is not known and these preliminary findings should prompt further studies of links between dysfunctional breathing, asthma, and viral infections.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-7"},"PeriodicalIF":1.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143189442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exacerbation during the first year of treatment affects lung function in subjects with asthma - a 10-year follow-up.","authors":"Pca Almeida, Ev Ponte, R Stelmach, Tw Harrison, N Scichilone, A Souza-Machado, Aa Cruz","doi":"10.1080/02770903.2025.2451690","DOIUrl":"10.1080/02770903.2025.2451690","url":null,"abstract":"<p><strong>Background: </strong>Inhaled corticosteroids (ICS) are the preferred treatment for asthma. They improve symptoms and reduce exacerbations and deaths, but their long-term impact on lung function loss remains unclear, especially after delayed treatment. We aimed to characterize the lung function trajectories in subjects with previously untreated severe asthma. The secondary aim was to identify predictors of FEV₁ decline, and future exacerbations.</p><p><strong>Methods: </strong>This is a <i>post-hoc</i> analysis that followed 184 subjects with asthma for 10 years after a delayed start of regular maintenance ICS treatment. Absolute lung function variation was calculated using two different baselines: (i) FEV₁ after one year of regular treatment (V₁) and (ii) best FEV₁ observed any time before the final visit.</p><p><strong>Results: </strong>Most individuals were female (84%) over 50 years old and had early-onset asthma with a median of 30 years without regular ICS treatment. Ninety-nine (54%) had an FEV1 decline above 25ml/year, using strategy (i). Those subjects were younger, had shorter duration of asthma, and had better lung function at V₁. Most of the participants without any obstructive pattern (74%) or with mild obstruction (64%) at V₁ showed a faster absolute FEV₁ decline, however PRISm showed faster relative decline than the other groups.</p><p><strong>Conclusion: </strong>This study showed improved symptoms and quality of life with variable lung function trajectories among individuals with asthma who start regular treatment after decades of delay. Additionally, exacerbation during the first year was a strong predictor of absolute FEV₁ decline and future exacerbations, while time without treatment was a predictor of relative reduction of FEV₁.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Computed tomography in severe asthma assessment: a systematic review.","authors":"Simona Luzzi, Tommaso Pianigiani, Akter Dilroba, Martina Meocci, Elisa Salvadori, Benedetta Picchi, Vittoria Ventura, Sara Croce, Laura Bergantini, Miriana D'Alessandro, Elena Bargagli, Paolo Cameli","doi":"10.1080/02770903.2025.2460549","DOIUrl":"10.1080/02770903.2025.2460549","url":null,"abstract":"<p><strong>Objective: </strong>Chest computed tomography (CT) is usually performed in patients with severe asthma (SA) to exclude concomitant conditions related to poor clinical control. Despite the growing evidence regarding the utility of CT in the characterization of morphological abnormalities and airway remodeling, its role in SA assessment is still largely unexplored. The aim of our systematic review was to evaluate published data investigating the role of chest CT in patients with SA.</p><p><strong>Data sources: </strong>The systematic search was conducted on the Medline database through the Pubmed search engine.</p><p><strong>Study selections: </strong>A total of 53 studies has been included.</p><p><strong>Results: </strong>Quantitative CT (qCT) parameters generally differ between SA patients compared to mild to moderate asthmatic patients or healthy controls and are related to functional decline. CT parameters allow to identify image-based clusters reflecting remodeling patterns and/or air trapping features. The detection of mucus plugs is more frequent in severe eosinophilic asthma, and it is related to marked airway obstruction and ventilation defects. Benralizumab treatment appears to reduce or vanish mucus plugging. Most studies regarding CT and bronchial thermoplasty (BT) detect the usefulness of this investigation in predicting treatment response. Lastly, conflicting results surround the relation between chest CT and SA assessment in children due to also the scarcity of studies focusing on pediatric population.</p><p><strong>Conclusions: </strong>The role of CT scans in SA is still debated. Most studies focus on the identification of CT-derived disease clusters while studies primarily evaluating the predicting role of CT scan to different biologics are lacking and could represent an interesting research area.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-10"},"PeriodicalIF":1.7,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143080118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual and system-level determinants of caregivers' quality of life among inner-city preschool children with asthma.","authors":"Olusegun Owotomo, Kristin A Riekert, Cynthia S Rand, Michelle N Eakin","doi":"10.1080/02770903.2025.2458516","DOIUrl":"10.1080/02770903.2025.2458516","url":null,"abstract":"<p><strong>Objective: </strong>Caregivers of children with asthma can become overwhelmed by the burden of care provision. Guided by the socioecological framework, we examined individual and system-level factors associated with caregiver health-related quality of life (HRQoL) among preschool children (aged two to six years) enrolled in a multilevel home- and school-based asthma educational intervention in Baltimore, Maryland.</p><p><strong>Methods: </strong>The primary outcome was caregiver HRQoL measured at baseline and six months. Independent variables were baseline individual-level factors (caregiver's health literacy, self-efficacy to manage asthma, and depressive symptoms) and system-level factors (barriers to asthma care measured in five subdomains-pragmatics, health knowledge and beliefs, expectations, skills, and marginalization-and neighborhood social cohesion). Multiple regression models were used to assess the association between baseline individual and system-level factors and caregiver HRQoL at baseline and six-month follow-up adjusting for the child's asthma control, caregiver's age, household income, and study arm assignment/intervention.</p><p><strong>Results: </strong>398 caregivers completed the baseline survey and 328 (82%) completed the six-month follow-up survey. In the adjusted multiple regression model, lower caregiver's health literacy and higher barriers to asthma care related to pragmatics were significantly associated with lower caregiver HRQoL at baseline (<i>b</i> = 0.38, 95% CI, 0.15-0.61, <i>p</i> = .002; and <i>b</i> = 0.01, 95% CI, 0.004-0.02, <i>p</i> < .001, respectively). The results were similar at the six-month follow-up.</p><p><strong>Conclusion: </strong>Caregiver health literacy and barriers to asthma care related to pragmatics and skills were found to be important determinants of asthma caregiver HRQoL. Addressing these factors may improve the quality of life among caregivers of preschool children with asthma.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-9"},"PeriodicalIF":1.7,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of Fluticasone Furoate/Umeclidinium/vilanterol (FF/UMEC/VI) on cough symptoms in adult patients with asthma, a randomized double-blind, placebo-controlled, parallel group study: Chronic Cough in Asthma (COCOA) study.","authors":"Etsuko Tagaya, Jun Shinada, Hiroyuki Nagase, Junko Terada-Hirashima, Masayuki Hojo, Naruhiko Sugihara, Osamitsu Yagi, Mayoko Tsuji, Tomohiro Akaba, Katsunori Masaki, Koichi Fukunaga, Hiroyuki Ohbayashi, Kaoru Chiba, Soichiro Hozawa, Ryo Atsuta, Yasuhiro Aoki, Hisato Hiranuma, Yasuhiro Gon, Akihiko Tanaka","doi":"10.1080/02770903.2025.2455416","DOIUrl":"10.1080/02770903.2025.2455416","url":null,"abstract":"<p><strong>Background: </strong>Persistent cough bothers many patients with asthma because it worsens their quality of life; therefore, it must be remedied immediately. The efficacy of triple therapy as a first-line treatment for cough remains unclear. To evaluate the effectiveness and safety of the triple therapy against persistent cough, the clinical effect of regular treatment with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) or placebo in adult patients with asthma was investigated.</p><p><strong>Methods: </strong>This randomized, double-blind, placebo-controlled, parallel-group multicenter trial recruited asthma patients with persistent cough from hospitals and primary care clinics between June 2022 and December 2023. Participants were randomly given FF/UMEC/VI 200/62.5/25 µg or placebo for 6 wk. The primary endpoint was the average change in the cough symptom score from baseline to week 6. Secondary outcomes were effectiveness on cough-related disease burdens (asthma control questionnaire [ACQ]-5, Leicester cough questionnaire [LCQ] and nighttime awakening). Furthermore, lung function and adverse events were evaluated.</p><p><strong>Results: </strong>The decrease from baseline in the cough symptom score at week 6 was significantly greater in the FF/UMEC/VI group than in the placebo group (<i>p</i> = 0.006). The ACQ-5 scores showed a greater decrease in the FF/UMEC/VI group than in the placebo group. The change from baseline in morning and evening FEV₁ increased in the FF/UMEC/VI group as with the results of peak expiratory flow. No significant adverse events associated with FF/UMEC/VI were noted.</p><p><strong>Conclusions: </strong>In asthma patients with persistent cough, FF/UMEC/VI showed an early response and a significant effect on cough and lung function for 6 wk of treatment.</p><p><p>This study is registered with jRCTs031210412.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-11"},"PeriodicalIF":1.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143059165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}